![]() |
Name |
cyclo-(l-Phe-l-Leu-l-Leu-l-Leu-l-Leu)
|
Molecular Formula | C32H51N5O5 | |
IUPAC Name* |
3-benzyl-6,9,12-tris(2-methylpropyl)-15-propyl-1,4,7,10,13-pentazacyclopentadecane-2,5,8,11,14-pentone
|
|
SMILES |
CCCC1NC(=O)C(CC(C)C)NC(=O)C(Cc2ccccc2)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC1=O
|
|
InChI |
InChI=1S/C32H51N5O5/c1-8-12-23-28(38)34-25(16-20(4)5)30(40)35-26(17-21(6)7)31(41)37-27(18-22-13-10-9-11-14-22)32(42)36-24(15-19(2)3)29(39)33-23/h9-11,13-14,19-21,23-27H,8,12,15-18H2,1-7H3,(H,33,39)(H,34,38)(H,35,40)(H,36,42)(H,37,41)/t23-,24-,25-,26-,27-/m0/s1
|
|
InChIKey |
JBRBYFAERJZNND-IRGGMKSGSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 585.79 | ALogp: | 2.6 |
HBD: | 5 | HBA: | 5 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 145.5 | Aromatic Rings: | 2 |
Heavy Atoms: | 42 | QED Weighted: | 0.286 |
Caco-2 Permeability: | -5.161 | MDCK Permeability: | 0.00013794 |
Pgp-inhibitor: | 0.983 | Pgp-substrate: | 0.17 |
Human Intestinal Absorption (HIA): | 0.151 | 20% Bioavailability (F20%): | 0.007 |
30% Bioavailability (F30%): | 0.008 |
Blood-Brain-Barrier Penetration (BBB): | 0.015 | Plasma Protein Binding (PPB): | 91.77% |
Volume Distribution (VD): | 0.392 | Fu: | 2.13% |
CYP1A2-inhibitor: | 0.005 | CYP1A2-substrate: | 0.04 |
CYP2C19-inhibitor: | 0.363 | CYP2C19-substrate: | 0.066 |
CYP2C9-inhibitor: | 0.604 | CYP2C9-substrate: | 0.77 |
CYP2D6-inhibitor: | 0.057 | CYP2D6-substrate: | 0.123 |
CYP3A4-inhibitor: | 0.929 | CYP3A4-substrate: | 0.19 |
Clearance (CL): | 2.037 | Half-life (T1/2): | 0.281 |
hERG Blockers: | 0.064 | Human Hepatotoxicity (H-HT): | 0.87 |
Drug-inuced Liver Injury (DILI): | 0.067 | AMES Toxicity: | 0.032 |
Rat Oral Acute Toxicity: | 0.965 | Maximum Recommended Daily Dose: | 0.027 |
Skin Sensitization: | 0.026 | Carcinogencity: | 0.021 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
Respiratory Toxicity: | 0.009 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003254 | ![]() |
0.622 | D0J7XL | ![]() |
0.435 | ||
ENC002515 | ![]() |
0.542 | D09OOV | ![]() |
0.387 | ||
ENC002514 | ![]() |
0.531 | D0K7NQ | ![]() |
0.351 | ||
ENC001909 | ![]() |
0.465 | D02XIY | ![]() |
0.343 | ||
ENC002910 | ![]() |
0.423 | D0M3FJ | ![]() |
0.338 | ||
ENC001983 | ![]() |
0.411 | D0X9PF | ![]() |
0.336 | ||
ENC005273 | ![]() |
0.411 | D0M1IO | ![]() |
0.325 | ||
ENC003175 | ![]() |
0.405 | D0H3MG | ![]() |
0.325 | ||
ENC005469 | ![]() |
0.405 | D02SBQ | ![]() |
0.323 | ||
ENC002373 | ![]() |
0.399 | D09PZZ | ![]() |
0.322 |